RUBRACA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated:
\n\u2022 for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.
\n\u2022 for the treatment of adult patients with deleterious BRCA mutation (germline and\/or somatic)-associated epithelial ovarian, fallopian tube, or primary peritoneal cancer who have been treated with two or more
\nchemotherapies. Select patients for therapy based on an FDA-approved companion diagnostic for RUBRACA.<\/p>\n
If rucaparib tablets are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) \/ +91 9811 747 774 (Mr. Neeraj).<\/p>\n","protected":false},"excerpt":{"rendered":"
Rubraca (rucaparib) is a medication used for the treatment of ovarian, fallopian tube and primary peritoneal cancer.<\/p>\n
DISEASE INDICATIONS-Gynaecological Cancer If you have a prescription from a Registered Medical Practitioner (RMP),\u00a0IPN<\/a> in Delhi can assist you in obtaining access to genuine medication.\u00a0 Our professional will provide you with a step-by-step guide on how to legally and safely import \u201crucaparib tablets\u201d based on the information you provide.<\/p>\n
\nMANUFACTURER-Clovis Oncology, Inc.
\nUSAGE-Oral
\nMEDICINE APPROVED BY-European Medical Agency (EMA), Food and Drug Administration (FDA)
\nSummary of FDA-approved use on approval date: Click Here<\/a>
\n(see Drugs@FDA for complete indication)<\/p>\nAccess the best support services globally<\/h4>\n